Get the Stockscreener App
146.47
0.62%
-0.92
After Hours:
145.70
-0.77
-0.53%
Biogen Inc stock is traded at $146.47, with a volume of 5.51M.
It is down -0.62% in the last 24 hours and down -6.11% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$147.39
Open:
$145.64
24h Volume:
5.51M
Relative Volume:
3.76
Market Cap:
$21.34B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
7.9733
EPS:
18.37
Net Cash Flow:
$1.77B
1W Performance:
-2.37%
1M Performance:
-6.11%
6M Performance:
-35.07%
1Y Performance:
-40.98%
1-Day Range:
$145.07
$147.85
1-Week Range:
$145.07
$154.24
52-Week Range:
$145.07
$268.30
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
146.47 | 21.34B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen (NASDAQ:BIIB) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - MSN
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Biogen in talks to move to MIT's Volpe development, sources say - NBC Boston
Biogen (NASDAQ:BIIB) Downgraded to Market Perform Rating by BMO Capital Markets - MarketBeat
Biogen stock under pressure as rare disease growth lags, says BMO - Investing.com
Neuroimmunology Drugs Market Key Players AnalysisAB Science - openPR
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Recombinant DNA Technology Market Expected to Reach Huge Growth - openPR
Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's Why - MarketBeat
Coagulation Factor Deficiency Market Key Players AnalysisPfizer Inc, Grifols, Biogen, Octapharma, Baxter. - openPR
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Eli Lilly's Alzheimer's treatment approved in China - Reuters
Eli Lilly's Alzheimer's treatment approved in China (Dec. 17) - Yahoo Canada Finance
Biogen's SWOT analysis: stock outlook amid alzheimer's drug launch and pipeline shifts - Investing.com
Multiple Sclerosis Therapeutics Market to See Booming Growth - openPR
Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR
Biogen Stock: Is BIIB Underperforming the Healthcare Sector? - Nasdaq
Biogen Stock: Is BIIB Underperforming The Healthcare Sector? - Barchart
Why are Biogen, Pfizer, and GSK Trading at a Discount? - Baystreet.ca
Franklin Resources Inc. Sells 13,723 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen downgraded to Hold by Stifelslower progress than expected - Marketscreener.com
Spinal Muscular Atrophy Market Overall Study Report 2024-2031 | - openPR
Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead - MSN
Biogen Inc. stock rises Monday, still underperforms market - MarketWatch
Netflix, Ford, Biogen: Trending tickers - Yahoo Finance
Biogen (NASDAQ:BIIB) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Analyst recommendations: Biogen, Broadcom, Exxon, UnitedHealth, Tesla, Twilio... - Marketscreener.com
World Investment Advisors LLC Acquires Shares of 5,766 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com
Quantinno Capital Management LP Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Hits New 12-Month LowShould You Sell? - MarketBeat
Oddo BHF Asset Management Sas Purchases Shares of 7,136 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug - BioPharma Dive
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Inspire Trust Co. N.A. - MarketBeat
Biogen ALS drug needs to be covered by MA plans, CMS says - MSN
Private Medicare plans must cover Biogen's ALS drug, US agency says - Reuters
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Kidney Disease - Biogen
Biogen's SWOT analysis: stock faces leqembi launch hurdles amid pipeline shifts - Investing.com
Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
Saratoga Research & Investment Management Sells 7,071 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Virtu Financial LLC Invests $4.11 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Escalator: Biogen, Accent Therapeutics, Xira Therapeutics and more - MM+M Online
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Geode Capital Management LLC - MarketBeat
Public Employees Retirement System of Ohio Has $10.26 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Nomura Asset Management Co. Ltd. Has $9.56 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Postpartum Depression Treatment Market Size, Trends, Growth, - openPR
Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.83%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):